Merck Hosts 2019 Investor Day Outlining Business Momentum, Strong Expected Growth and Focus on Innovative Research and Development
Dateline City:
KENILWORTH, N.J.
- Momentum Across Key Pillars Expected to Drive Strong Revenue Growth Every Year Over the Next Five Years, Including 2023 – the Year of Greatest Anticipated Impact of JANUVIA® (sitagliptin) Loss of Exclusivity (LOE)
- Meaningful Operating Margin Expansion Expected, Driven by Disciplined Expense Management and Operating Model Evolution
- Broad Mid-to-Late Stage Pipeline Opportunities in Areas of Significant Unmet Medical Need to Drive Leadership Over the Next Decade, Including the Potential for More Than 50 New Indications in Oncology Over the Next Five Years
- Reinvigorated Early Pipeline Efforts Spanning a Diverse Set of Disease Areas to Deliver Important Medical Advances
KENILWORTH, N.J.–(BUSINESS WIRE)–At a meeting with the investment community today, Merck (NYSE: MRK), known as MSD outside the United States and Canada, will outline how its science-led strategy and broad pipeline of promising transformative therapies and vaccines will position the company to deliver strong growth and shareholder value over the long term.
Language:
English
Contact:
Media:
Jenn Mauer
(908) 740-1801
Jess Fine
(908) 740-1707
Pamela Eisele
(267) 305-3558
Investors:
Teri Loxam
(908) 740-1986
Peter Dannenbaum
(908) 740-1037
Michael DeCarbo
(908) 740-1807
Ticker Slug:
Ticker:
MRK
Exchange:
NYSE
@Merck